๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Cognitive functioning in a hypnotic drug trial

โœ Scribed by David Wheatley


Publisher
John Wiley and Sons
Year
1986
Tongue
English
Weight
423 KB
Volume
1
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

โœฆ Synopsis


In a 2 week comparative trial between lormetazepam (LMA) and temazepam (TEM) in 162 insomniac patients, Critical Flicker Fusion Threshhold (CFFT) and Digit Symbol Substitution (DSS) tests were performed, pre-treatment and at days 7 and 14. With neither drug was there any difference in C m , but highly significant improvement in DSS (p < 0.001). Patients completed daily visual analogue scales concerned with various sleep parameters and daytime effects. Sleep was significantly improved with both drugs from day 1 onwards, as were daytime general wellbeing and alertness. There was significant improvement in daytime balance and coordination in the LMA group (p < 0-001 by day 14) but not in the TEM group. Daytime anxiety improved significantly in both groups, but on day 14 this improvement was still significant in the LMA group (p < 0.001) but not in the TEM group. The incidence of daytime fatigue (p < 0.001), drowsiness (p < 0.02) and headache (p < 0.001) were significantly reduced with LMA and daytime fatigue (p < 0-01) and headache (p < 0.001) with TEM, but with no significant between group differences. The severity of daytime fatigue was significantly less with LMA than with TEM (p < 0-05).


๐Ÿ“œ SIMILAR VOLUMES


Cognitive functioning in depression
โœ John A. Sweeney; Scott Wetzler; Peter Stokes; James Kocsis ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 522 KB
Assessing cognitive function in clinical
โœ Jennifer H. Barnett; Trevor W. Robbins; Verity C. Leeson; Barbara J. Sahakian; E ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 435 KB

Cognitive dysfunction in schizophrenia is an important target for novel therapies. Effectively measuring the cognitive effects of compounds in clinical trials of schizophrenia could be a major barrier to drug development. The Measurement and Treatment Research to Improve Cognition in Schizophrenia (

Cognitive functioning in breast cancer s
โœ Heather S. L. Jim; Kristine A. Donovan; Brent J. Small; Michael A. Andrykowski; ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 136 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND: The current study was performed to determine whether neuropsychologic functioning differs in breast cancer survivors 6 months after the completion of adjuvant treatment compared with women without cancer. ## METHODS: Participants were 187 women who were diagnosed with

Effects of discontinuing benzodiazepine-
โœ Kenichi Tsunoda; Hiroyuki Uchida; Takefumi Suzuki; Koichiro Watanabe; Tetsumori ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 144 KB ๐Ÿ‘ 2 views

## Abstract ## Objective Benzodiazepines (BZDs) have been reported to cause negative impacts on body stability and cognitive functions, which in turn could result in lethal incidents, including falls, especially in the elderly. This fact notwithstanding, no systematic trial has evaluated the feasi

French recommendations for clinical drug
โœ Dr. Bernard Michel; Roland Sambuc; Jean-Claude Scotto ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 449 KB ๐Ÿ‘ 2 views

## Abstract A consensus conference on the topic of clinical drug trials in cognitive disorders of the elderly was held in Marseille on January 28โ€“29, 1993. At the end of this conference, several recommendations were made. Drugs used in trials must be chosen according to solid neurobiological eviden